Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer

Expert Opinion on Biological Therapy

Volumn 12, Issue 12, 2012, Pages 1669-1678

  Kyula, Joan N ^a   Roulstone, Victoria ^a   Karapanagiotou, Eleni M ^a   Melcher, Alan A ^b   Harrington, Kevin J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Head and neck cancer; Oncolytic virus; Ras pathway; Reovirus; Targeted therapy

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOLYTIC REOVIRUS TYPE 3; ONCOLYTIC VIRUS; PEXASTIMOGENE DEVACIREPVEC; TALIMOGENE LAHERPAREPVEC; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG TOLERABILITY; FLU LIKE SYNDROME; HEAD AND NECK CANCER; HUMAN; LIVER CANCER; MELANOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RADIATION DOSE; REVIEW;

CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; MAMMALIAN ORTHOREOVIRUS 3; ONCOLYTIC VIROTHERAPY;

MAMMALIAN ORTHOREOVIRUS 3; ORTHOREOVIRUS;

EID: 84869477859     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.745507     Document Type: Review

References (50)

1. Cripps C, Winquist E, Devries MC, et al. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol 2010;17:37-48
2. Dias JD, Liikanen I, Guse K, et al. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin Cancer Res 2010;16:2540-9
3. Mehanna H, Jones TM, Gregoire V, et al. Oropharyngeal carcinoma related to human papillomavirus. BMJ 2010;340:c1439
4. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. New Engl J Med 2003;349:2091-8
5. Donnelly OG, Errington-Mais F, Steele L, et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther 2011;In press 6. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12:6737-47
6. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colonystimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763-71
7. Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010;16:4005-15
8. Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial. Lancet Oncol 2008;9:533-42
9. Liu TC, Hwang T, Park BH, et al. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008;16:1637-42
10. Heo J, Breitbach CJ, Moon A, et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: Preclinical and clinical demonstration of combination efficacy. Mol Ther 2011;19:1170-9
11. Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011;477:99-102
12. Adams DJ, Ridinger DN, Spendlove RS, et al. Protamine precipitation of two reovirus particle types from polluted waters. Appl Envir Microbiol 1982;44:589-96
13. Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963;77:29-37
14. Minuk GY, Paul RW, Lee PW. The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J Med Virol 1985;16:55-60
15. Tai JH, Williams JV, Edwards KM, et al. Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. J Infect Dis 2005;191:1221-4
16. van den Wollenberg DJM, van den Hengel SK, Dautzenberg IJC, et al. A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting. Gene Ther 2008;15:1567-78
17. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977;54:307-15
18. Duncan MR, Stanish SM, Cox DC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 1978;28:444-9
19. Strong JE, Lee PW. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 1996;70:612-16
20. Coffey MC, Strong JE, Forsyth PA, et al. Reovirus therapy of tumors with activated Ras pathway. Science 1998;282:1332-4
21. Strong JE, Coffey MC, Tang D, et al. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J 1998;17:3351-62
22. Bos JL. ras oncogenes in human cancer: A review. Cancer Res 1989;49:4682-9
23. Rogers SJ, Harrington KJ, Rhys-Evans P, et al. Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metast Rev 2005;24:47-69
24. Vorburger SA, Pataer A, Swisher SG, et al. Genetically targeted cancer therapy: Tumor destruction by PKR activation. Am J Pharmacogenomics 2004;4:189-98
25. Meurs E, Chong K, Galabru J, et al. Molecular cloning and characterization of the human double-stranded RNAactivated protein kinase induced by interferon. Cell 1990;62:379-90
26. Smakman N, van den Wollenberg DJ, Elias SG, et al. KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2006;66:5403-8
27. Marcato P, Shmulevitz M, Pan D, et al. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 2007;15:1522-30
28. Alain T, Kim TS, Lun X, et al. Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol Ther 2007;15:1512-21
29. Comins C, Heinemann L, Harrington K, et al. Reovirus: Viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol) 2008;20:548-54
30. Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008;14:7127-37
31. Gollamudi R, Ghalib MH, Desai KK, et al. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 2010;28:641-9
32. Adair RA, Roulstone V, Scott KJ, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Translat Med 2012;4:138ra77
33. Hirasawa K, Nishikawa SG, Norman KL, et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003;63:348-53
34. Qiao J, Wang H, Kottke T, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008;14:259-69
35. Sobotkova E, Duskova M, Eckschlager T, et al. Efficacy of reovirus therapy combined with cyclophosphamide and gene-modified cell vaccines on tumors induced in mice by HPV16-transformed cells. Int J Oncol 2008;33:421-6
36. Kottke T, Thompson J, Diaz RM, et al. Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res 2009;15:561-9
37. White CL, Twigger KR, Vidal L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 2008;15:911-20
38. Harrington KJ, Vile RG, Melcher A, et al. Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 2010;21:91-8
39. Comins C, Spicer J, Protheroe A, et al. REO-10: A phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 2010;16:5564-72
40. Lolkema MP, Arkenau HT, Harrington K, et al. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 2011;17:581-8
41. Morris DG, Feng X, Difrancesco LM, et al. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin) in patients with advanced solid tumors. Invest New Drugs 2012 (in press).
42. Forsyth P, Roldan G, George D, et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008;16:627-32
43. Harrington KJ, Melcher A, Vassaux G, et al. Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther 2008;10:362-70
44. Twigger K, Vidal L, White CL, et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 2008;14:912-23
45. Harrington KJ, Karapanagiotou EM, Roulstone V, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 2010;16:3067-77
46. Kumar S, Gao L, Yeagy B, et al. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008;10:371-9
47. Pandha HS, Heinemann L, Simpson GR, et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 2009;15:6158-66
48. Heinemann L, Simpson GR, Boxall A, et al. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 2011;11:221
49. Roulstone V, Twigger K, Zaidi S, et al. Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther 2012;In press 51. Karapanagiotou EM, Roulstone V, Twigger K, et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 2012;18:2080-9
50. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Reg 1984;22:27-55